Prof Matthew Galsky speaks to ecancer in an online interview for the virtual ASCO 2020 meeting.
He discusses IMvigor130 which is a multi-centre, randomised, placebo-controlled phase 3 study looking at atezolizumab with or without chemotherapy in metastatic urothelial cancer.
Prof Galsky explains why before the trial even completed enrolment, clinical practise was already changed, based on patient PD-L1 expression.
He then explains the history of the IMvigor130 trial and the results from ESMO 2019 up to ASCO 2020.
Prof Galsky going into depth discussing the biomarkers, and whether they were predictive or prognostic (PD-L1, TMB, TGF-beta fibroblast).
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.